Therapeutic effects of Holmium-166 chitosan complex in rat brain tumor model.
This study examined the effectiveness of Holmium-166 (Ho-166) chitosan complex therapy for a malignant glioma. Cultured C6 glioma cells (100,000 in 5 microl) were injected into the caudate/putamen of 200-250 gram Wistar rats. Five days later, a Ho-166 chitosan complex was injected into the same site of the glioma injection. Four injection doses were administered: the control group received PBS 10 microl, group 1 received an injection of 100 microCi (10 microl), group 2 received an injection of 50 microCi (5 microl), and group 3 received an injection of 10 microCi (1 microl). The average tumor volume for each group was 1.385 mm3 for the control group, 0.036 mm3 for group 1, 0.104 mm3 for group 2, and 0.111 mm3 for group 3. Compared with the control group, the size of the tumors in groups 1, 2 and 3 was reduced by an average of 97.4%, 92.5% and 91.9%, respectively. The Kaplan-Meier survival curve of group 2 was the longest, followed by groups 3, group 1 and the control. The mean survival was 22.8, 59, 60, and 44.6 days for the control group and groups 3, 2 and 1, respectively. H-E staining revealed that group 2 yielded the best results in the destruction of the malignant glioma. TUNEL staining and immunohistochemical studies indicated apoptotic features. The Ho-166 chitosan complex proved to be effective in destroying the malignant glioma.
Huh
Ryoong
R
Department of Neurosurgery, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun- gu, Seoul 120-752, Korea.
Park
Yong Sook
YS
Lee
Jong Doo
JD
Chung
Young Sun
YS
Park
Yong Gou
YG
Chung
Sang Sup
SS
Chang
Jin Woo
JW
D000818:Animals; D001918:Brachytherapy; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology; D045744:Cell Line, Tumor; D002686:Chitin / Q000031:analogs & derivatives / Q000494:pharmacology*; D004195:Disease Models, Animal; D005910:Glioma / Q000000981:diagnostic imaging* / Q000401:mortality / Q000473:pathology; D006695:Holmium / Q000494:pharmacology*; D011868:Radioisotopes / Q000494:pharmacology*; D011877:Radionuclide Imaging; D051381:Rats; D017208:Rats, Wistar
D011868:Radioisotopes; D002686:Chitin; D006695:Holmium
Br J Neurosurg. 1999 Jun;13(3):256-64
10562835
J Neurosurg. 1999 Jan;90(1):125-32
10413165
Eur J Nucl Med. 2000 Jul;27(7):842-6
10952496
Neurosurgery. 2000 Oct;47(4):931-8; discussion 938-9
11014433
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):831-6
11020581
Cancer Treat Rev. 2000 Dec;26(6):397-409
11139371
J Neurosurg. 2000 Dec;93(6):917-26
11117863
J Neurooncol. 2000 Aug;49(1):27-39
11131984
Eur J Nucl Med. 2001 Apr;28(4):489-97
11357500
Neuro Oncol. 1999 Jan;1(1):69-80
11550304
Neurosurgery. 2002 Jan;50(1):41-6; discussion 46-7
11844233
Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):221-30
11926384
Eur J Pharm Biopharm. 2004 Jan;57(1):123-31
14729088
Neurosurgery. 1987 Aug;21(2):201-6
2821446
Br J Neurosurg. 1989;3(2):197-210
2803583
Anticancer Res. 1991 Mar-Apr;11(2):719-27
2064325
J Nucl Med. 1991 Nov;32(11):2139-43
1941151
Neurosurgery. 1992 Aug;31(2):336-43
1513439
Neurosurgery. 1993 May;32(5):716-20; discussion 720
8388081
Neurosurgery. 1994 Nov;35(5):822-9; discussion 829-30
7838329
Stereotact Funct Neurosurg. 1995;64 Suppl 1:239-48
8584834
J Nucl Med. 1997 May;38(5):697-702
9170430
Arzneimittelforschung. 1998 Mar;48(3):300-4
9553690
J Nucl Med. 1998 Dec;39(12):2161-6
9867162
Neurosurgery. 2000 May;46(5):1123-8; discussion 1128-30
10807244